Peptech investees pick up grant and knighthood
17 June, 2004 by Renate KrelleThe day after Peptech (ASX: PTD) celebrated the knighting of its investee company Domantis’ co-founder Dr Gregory Winter, its joint venture partner Biosceptre International was tapped for a $2.1 million START grant to develop a skin cancer therapeutic.
Novogen establishes Australian site for breast cancer study
16 June, 2004 by Graeme O'NeillThe Royal Women’s Hospital in Melbourne has been announced as one of two international sites for a phase II clinical trial of phenoxodiol, the promising chemotherapy-boosting compound phenoxodiol, developed by Marshall Edwards (LSE AIM: MSH, NASDAQ:MSHL), a US subsidiary of Sydney pharmaceutical company Novogen (ASX: NRT, NASDAQ: NVGN).
BIO 2004: Best is yet to come, industry heavyweights predict
16 June, 2004 by Melissa TrudingerFour industry visionaries provided a glimpse of the biotechnology industry's future at the final plenary session of BIO 2004, which wrapped up in San Francisco last week.
Antisense eagerly awaits MS therapy result
15 June, 2004 by Renate KrelleAs Biogen Idec and Elan await approval from the FDA and the European Medicines Agency for their multiple sclerosis therapeutic, Antegren, Melbourne-based Antisense Therapeutics (ASX:ANP) will also be watching with bated breath.
CSIRO halves GroPep investment
15 June, 2004 by Renate KrelleThe CSIRO -- formerly the largest shareholder in Adelaide-based biopharma GroPep (ASX:GRO) -- last week halved its shareholding in the company, selling 5 million shares valued at just under $3.5 million.
GTG firms up O'Connor partnership
15 June, 2004 by Graeme O'NeillGenetic Technologies (ASX:GTG) has sealed its broad strategic alliance with Perth-based biotech research agency, the CY O'Connor ERADE Village Foundation (CYO), foreshadowed in October last year.
C3 signs Italian distributor
11 June, 2004 by Renate KrellePerth-based tissue engineering company Clinical Cell Culture (C3, ASX:CCE) has signed Rome-based Health Defence to distribute its CellSpray and ReCell products in Italy.
XCeed appoints manufacturer
11 June, 2004 by Renate KrelleRecently-listed XCeed Biotechnology (ASX:XBL) has announced that its subsidiary Polymerco will use Melbourne-based AorTech to manufacture its biodegradeable polyurethane. The product has applications in orthapaedics, wound repair, drug delivery and stents.
BIO 2004: Big-spending Beattie bids more on biotech
10 June, 2004 by Melissa TrudingerQueensland premier Peter Beattie has used the BIO 2004 conference in San Francisco as a platform to announce more than AUD$45 million of funding for clinical and medical research, clinical trials, smart foods and research facilities in the state.
Panbio, La Trobe win malaria diagnostic grant
10 June, 2004 by Graeme O'NeillBrisbane diagnostics company Panbio (ASX:PBO) and La Trobe University have received a $117,000 development grant from the National Health and Medical Research Council to develop a simple, rapid, point-of-care diagnostic for malaria.
Biota steps up Glaxo lawsuit
10 June, 2004 by Renate KrelleBiota Holdings (ASX:BTA) has filed a statement of claim in the Victorian Supreme Court, moving its litigation against GlaxoSmithKline forward a step.
AGT merger partner's cancer drug results promising
10 June, 2004 by Melissa TrudingerClinical results from AGT Bioscience's merger partner ChemGenex Therapeutics' Phase I/II trial of cancer drug Quinamed, released yesterday at ASCO in New Orleans and BIO in San Francisco, have shown promising anti-cancer activity, the company has claimed.
LCT diabetes technology makes debut in Italian trial
09 June, 2004 by Graeme O'NeillItalian researchers have transplanted insulin-secreting pancreatic islet cells into a 37-year old man with type 1 diabetes, in the first of a 10-patient pilot trial of a potentially revolutionary treatment for diabetes developed by Australian biomedical company Living Cell Technologies (NSX:LCT).
Chemeq raises $10m
09 June, 2004 by Graeme O'NeillPerth pharmaceutical company Chemeq (ASX:CMQ) has raised AUD$10 million from a share placement to institutional and private clients with Bell Potter Securities.
ASCO: Celgene says blood cancer patients respond to Thalidomide
08 June, 2004 by Staff WritersThalidomide, a cause of severe birth defects in children in the 1950's, and currently approved for the treatment of leprosy, was found to be effective in a clinical trial for treating patients with multiple myeloma, a form of blood cancer.
